A series of novel (E)-4-oxo-2-crotonamide derivatives were designed and synthesized to find potent antituberculosis agents. All the target compounds were evaluated for their in vitro activity against Mycobacterium tuberculosis H37Rv(MTB). Results reveal that 4-phenyl moiety at part A and short methyl group at part C were found to be favorable. Most of the derivatives displayed promising activity against
[EN] KYNURENINE 3-HYDROXYLASE INHIBITORS FOR THE TREATMENT OF DIABETES<br/>[FR] INHIBITEURS DE LA KYNURENINE 3-HYDROXYLASE POUR LE TRAITEMENT DU DIABETE
申请人:MERCK PATENT GMBH
公开号:WO2004060369A1
公开(公告)日:2004-07-22
The present invention relates to the use of at least one compound with inhibitory activity on kynurenine 3-hydroxylase for the preparation of a medicament for the prevention and/or treatment of diabetes.
asymmetric transformation and a conjugate addition of N-nucleophiles to the corresponding aroylacrylic acids. Further transformations to 3,4-dichlorobenzoylalanine and aroyl-l-alanines via periodate oxidation and stereoselective reduction to N-substituted syn-4-aryl-4-hydroxy-2-aminobutanoic acids are also described.
Solid-Support Synthesis of Natural Product-like Compounds Derived from<scp>d</scp>-(-)-Ribose
作者:Robert Häner、Roland Messer、Xavier Pelle、Andreas L. Marzinzik、Hansjörg Lehmann、Jürg Zimmermann
DOI:10.1055/s-2005-872684
日期:——
The synthesis of natural product-like compounds on solid support is described. Starting from a readily accessible d-(-)-ribose derivative, a tricyclic scaffold is prepared in five steps. After coupling onto solid supports bearing different substituents (PAL resins), the scaffold can be further derivatised at two diversity points. Representative derivatives obtained by this diversity-oriented procedure are described.
Kynurenine 3-hydroxylase inhibitors for the treatment of diabetes by increasing the number of islets of langerhans cells
申请人:Autier Valerie
公开号:US20060052456A1
公开(公告)日:2006-03-09
The present invention relates to the use of at least one compound with inhibitory activity on kynurenine 3-hydroxylase, for the preparation of a medica ment for increasing the number of islets of Langerhans cells, which is intended especially for the prevention and/or treatment of diabetes.